A clinical study of autologous tumor vaccine in patients with malignant tumors
- VernacularTitle:自体肿瘤疫苗主动特异性免疫治疗恶性肿瘤的临床研究
- Author:
Dong WANG
;
Zengpeng LI
;
Hualiang XIAO
- Publication Type:Journal Article
- Keywords:
malignant neoplasms;
cancer vaccine;
immunotherapy, active
- From:
Medical Journal of Chinese People's Liberation Army
2001;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical significance and the mechanism of immunotherapy with autologous tumor vaccine. Methods 400 patients with pathological diagnosis of malignant tumor were enrolled in this study. 5 days after operation, the patients received vaccination of autologous tumor vaccine every 2-3 days for 5 times. 3 days before and 7 days after administrations, the peripheral blood mononuclear cells (PBMC) were isolated to assay the alteration in the proportions of CD3,CD4,CD8,CD4/CD8, and NK cells. Meanwhile, serum IL-2 and IFN-? were measured. Results After active immunotherapy with autologous tumor vaccine, the proportions of CD4 and CD4/CD8 were significantly elevated, while the proportion of CD8 and NK showed no difference. All the patients tolerated the vaccine well without serious side effects, such as skin ulceration. Conclusion The autologous tumor vaccine can elicit specific cellular immune response, and may be a potential approach to treat the cancer.
